BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported Q2 2017 earnings this Morning, coming in at ($0.21) per share, missing Wall Street’s estimates of ($0.19) per Share. Revenue for the quarter came in at $3.10 million missing the streets estimates of $5.79 million
Analyst Coverage For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
These are 1 Hold Rating, 7 Buy Ratings .
The current consensus rating for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Buy (Score: 2.88) with a consensus target price of $8.50 , a potential (66.67% upside)Recent Insider Trading for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
- On 3/20/2017 Thomas R Staab II, CFO, sold 3,250 with an average share price of $9.20 per share and the total transaction amounting to $29,900.00.
- On 3/10/2017 Thomas R Staab II, Insider, sold 3,250 with an average share price of $9.06 per share and the total transaction amounting to $29,445.00.
- On 3/8/2017 Thomas R Staab II, Insider, sold 6,500 with an average share price of $8.43 per share and the total transaction amounting to $54,795.00.
- On 3/6/2017 Thomas R Staab II, Insider, sold 3,250 with an average share price of $7.90 per share and the total transaction amounting to $25,675.00.
- On 12/19/2016 Thomas R Staab II, Insider, sold 3,250 with an average share price of $7.45 per share and the total transaction amounting to $24,212.50.
- On 9/14/2016 Alane P Barnes, VP, sold 8,357 with an average share price of $4.27 per share and the total transaction amounting to $35,684.39.
Recent Trading for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares of BioCryst Pharmaceuticals, Inc. closed the previous trading session at 4.69 down -0.41 -8.04% with 656,416 shares trading hands.